The IPO Buzz: HawkEye 360 (HAWK Proposed) Tops Short List in Early May

HawkEye 360 (HAWK Proposed), a satellite company that runs a satellite signal-processing platform,  is the headliner for the first week of  May 2026. With estimated IPO proceeds of $400 million, HawkEye 360 is the single largest deal this week. HawkEye 360 represents about 57 percent of the proceeds – in U.S. dollar volume – for this week’s IPO Calendar of five deals that aim to raise  $767.54 million.

Let’s take a quick look at the deals.

HawkEye 360, a U.S. Department of Defense contractor, is offering 16 million shares at $24.00 to $26.00 to raise $400 million – if priced at the $25.00 mid-point. This is a New York Stock Exchange listing. (Note: The Department of Defense is also known as the Department of War.)

Goldman Sachs, Morgan Stanley, RBC Capital Markets, Jefferies, BofA Securities, Baird, Raymond James and William Blair are the joint book-runners.

“I love the sector,” an IPO pro says.

Suja Life (SUJA Proposed) is the second-largest deal on this week’s IPO Calendar. Suja Life, an Oceanside, California-based organic juice company, is offering 8.89 million shares at a price range of $21.00 to $24.00 to raise $200 million. This is a NASDAQ listing.

Goldman Sachs, Jefferies, William Blair, BofA Securities and Evercore ISI are the joint book-runners.

Both HawkEye 360 and Suja Life are set to price on Wednesday night, May 6, 2026, to trade Thursday, May 7.

A SPAC IPO – Vernal Capital Acquisition (VECAU Proposed) – is also on the IPO runway with plans to raise $100 million. The China-focused SPAC’s IPO pricing is set for Tuesday night, May 5, 2026, to trade Wednesday, May 6, on the NASDAQ. D. Boral Capital is the sole book-runner.

Rare Earths America (REA proposed), an exploration-stage mining company focused on critical minerals, intends to raise $50 million with its IPO this week. This is an NYSE – American Exchange (NYSE-AmEx) listing. Cantor and Stifel are the joint book-runners.

Optimi Health (OPTH Proposed), a small NASDAQ uplisting deal and a carry-over from recent weeks, rounds out this week’s IPO Calendar. The Canadian company is conducting clinical trials to evaluate psilocybin and MDMA – two controlled substances – as treatments for treatment-resistant depression and PTSD.

Optimi Health’s  $17.5 million uplisting deal is still awaiting NASDAQ approval. This is an uplisting from the OTC market. Joseph Gunnar & Co. is the sole book-runner.

Stay tuned.

(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.

To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.

Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.

Source: https://www.iposcoop.com/the-ipo-buzz-hawkeye-360-hawk-proposed-tops-short-list-in-early-may/